explore -WSS

explore

author：leisure time 2025-09-14 21:54:59 - browse：1

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

entertainment

focus

WSS

Alabama hospital puts IVF treatments on hold

NIH study of ME/CFS points to clear biological hallmarks

New documents shed light on MD Anderson Cancer Institute feud

Alabama IVF ruling threatens families facing fatal genetic disease

Teladoc has a new CEO, but challenges remain the same

Alabama hospital puts IVF treatments on hold

knowledge

explore

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Moderna says combo Covid

Drug repurposing or repositioning? The language matters

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Cancer drug shortages should be causing more outrage

New report analyzes digital physical therapy solutions' effectiveness

Heart attack and stroke risk calculators need revising

Study: Why relieving medical debt did not improve financial outcomes

In Memoriam: Notable people who died in 2023

New documents shed light on MD Anderson Cancer Institute feud

focus

How faith leaders like me can help address America's obesity epidemic

Ed Silverman on new gene therapies, biosimilars, coffee, and more

In utero gene editing: an explainer

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

New report analyzes digital physical therapy solutions' effectiveness

Alabama frozen embryo ruling has major implications for IVF clinics

entertainment

focus

focus

leisure time